SCHEMBL4673044

SCHEMBL4673044

O=C(C=C(O)c1nc[nH]n1)c1ccoc1Oc1cccc(Cl)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.36
CYP3A4 P08684 1/20 0.35
LMNA P02545 1/20 0.34
ABL1 P00519 1/20 0.34
XDH P47989 1/20 0.33
SLC22A12 Q96S37 1/20 0.33
HAO1 Q9UJM8 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
PDE4B Q07343 1/20 0.32
GRM5 P41594 1/20 0.32
FKBP1A P62942 1/20 0.32
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
KDM4E B2RXH2 2/20 0.31
PTPN1 P18031 1/20 0.31
PTGER4 P35408 1/20 0.31
ICAM1 P05362 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4676663 0.88 CYP1A1 (0.36) CYP3A4LMNACYP1A2CYP2C9CYP2C19
SCHEMBL4674895 0.88 KDM4E (0.40) KDM4CLMNAHAO1KDM4E
SCHEMBL4674141 0.88 CDH1 (0.33) LMNATDP1
SCHEMBL4672937 0.85 KDM4E (0.38) CYP1A2CYP2C9CYP2C19KDM4EICAM1
SCHEMBL4672137 0.84 CYP3A4 (0.40) KDM4CCYP3A4LMNAABL1HAO1
SCHEMBL4672494 0.82 LMNA (0.39) KDM4CCYP3A4LMNAABL1XDH
SCHEMBL4674689 0.82 ADRB2 (0.38) CYP3A4RXRARXRBRXRGPTPN1
SCHEMBL4675173 0.82 RAB9A (0.33) KDM4CABL1KDM4ETDP1
SCHEMBL4679724 0.81 CYP1A1 (0.30)
SCHEMBL4674086 0.81 CYP1A1 (0.36) KDM4CLMNAKDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 KDM4C 785/4885CYP3A4 4/4885LMNA 659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.